U.S. markets open in 8 hours 36 minutes
  • S&P Futures

    4,433.75
    +0.75 (+0.02%)
     
  • Dow Futures

    34,794.00
    +51.00 (+0.15%)
     
  • Nasdaq Futures

    15,165.25
    -29.50 (-0.19%)
     
  • Russell 2000 Futures

    2,282.70
    +5.70 (+0.25%)
     
  • Crude Oil

    76.11
    +0.66 (+0.87%)
     
  • Gold

    1,749.90
    -2.10 (-0.12%)
     
  • Silver

    22.62
    -0.07 (-0.30%)
     
  • EUR/USD

    1.1699
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4840
    -1.4840 (-100.00%)
     
  • Vix

    18.76
    -17.75 (-100.00%)
     
  • GBP/USD

    1.3713
    +0.0008 (+0.06%)
     
  • USD/JPY

    111.1740
    +0.1960 (+0.18%)
     
  • BTC-USD

    42,696.48
    -1,267.55 (-2.88%)
     
  • CMC Crypto 200

    1,058.29
    -43.23 (-3.92%)
     
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • Nikkei 225

    30,125.52
    -114.54 (-0.38%)
     

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So, the natural question for Reneo Pharmaceuticals (NASDAQ:RPHM) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

Check out our latest analysis for Reneo Pharmaceuticals

How Long Is Reneo Pharmaceuticals' Cash Runway?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When Reneo Pharmaceuticals last reported its balance sheet in March 2021, it had zero debt and cash worth US$91m. In the last year, its cash burn was US$23m. Therefore, from March 2021 it had 4.0 years of cash runway. There's no doubt that this is a reassuringly long runway. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Reneo Pharmaceuticals' Cash Burn Changing Over Time?

Reneo Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. During the last twelve months, its cash burn actually ramped up 62%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Easily Can Reneo Pharmaceuticals Raise Cash?

While Reneo Pharmaceuticals does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Reneo Pharmaceuticals has a market capitalisation of US$207m and burnt through US$23m last year, which is 11% of the company's market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

How Risky Is Reneo Pharmaceuticals' Cash Burn Situation?

It may already be apparent to you that we're relatively comfortable with the way Reneo Pharmaceuticals is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. Based on the factors mentioned in this article, we think its cash burn situation warrants some attention from shareholders, but we don't think they should be worried. Separately, we looked at different risks affecting the company and spotted 3 warning signs for Reneo Pharmaceuticals (of which 1 is a bit unpleasant!) you should know about.

If you would prefer to check out another company with better fundamentals, then do not miss this free list of interesting companies, that have HIGH return on equity and low debt or this list of stocks which are all forecast to grow.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.